CompletedPhase 2NCT04712669
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Altavant Sciences GmbH
- Principal Investigator
- Howard M Lazarus, MD, FCCPAltavant Sciences GmbH
- Intervention
- rodatristat ethyl 300 mg tablet BID(drug)
- Enrollment
- 108 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (30)
- Arizona Pulmonary Specialists, Phoenix, Arizona, United States
- University of California San Diego Health Sciences, La Jolla, California, United States
- VA Greater LA Healthcare System/UCLA, Los Angeles, California, United States
- Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Jeffrey S. Sager, MD Medical Corporation, Santa Barbara, California, United States
- University of Colorado, Aurora, Colorado, United States
- George Washington University Medical Center, Washington D.C., District of Columbia, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- The University of Kansas Medical Center, Kansas City, Kansas, United States
- Norton Pulmonary Specialists, Louisville, Kentucky, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04712669 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →